Search Results - "Asmis, T.R."

Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo by Vickers, M.M, Powell, E.D, Asmis, T.R, Jonker, D.J, Hilton, J.F, O’Callaghan, C.J, Tu, D, Parulekar, W, Moore, M.J

“…Abstract Background The effect of comorbidity, age and performance status (PS) on treatment of advanced pancreatic cancer is poorly understood. We examined…”
Get full text

P5 Chemotherapy home infusion: improving patient safety and the patient experience with the elastomeric infusor at the Ottawa Hospital Cancer Centre by Eleuterio, M, McLaurin, C, Liska, C, DeGrasse, C, Karrei, I, Duchene, G, Sabourin, M, Asmis, T.R

Get full text

895P Correlating peptidylglycine alpha-amidating monooxygenase (PAM) expression with clinicopathologic variables in gastrointestinal (GI) neuroendocrine tumors (NETs) by Sim, J., Marginean, H., Jirovec, A., Vickers, M.M., Marginean, E.C., Asmis, T.R., Marginean, B., Goodwin, R.A.

Get full text

702PSTANDARD CLINICAL PRACTICE OF FOLFIRINOX (FFX) IN ADVANCED/METASTATIC PANCREATIC CANCER (PC) PATIENTS: A CANADIAN RETROSPECTIVE REGISTRY by Maroun, J.A., Ko, Y., Ghafoor, A., Kavan, P., Cripps, M., Jonker, D., Goel, R., Asmis, T.R., Goodwin, R., Tsvetkova, E., Marginean, H.

“…Abstract Aim: FFX has been adopted as first-line treatment in patients with good performance status (PS) and liver function. This registry further investigates…”
Get full text

Standard Clinical Practice of Folfirinox (Ffx) in Advanced/Metastatic Pancreatic Cancer (Pc) Patients: a Canadian Retrospective Registry by Maroun, J.A., Ko, Y., Ghafoor, A., Kavan, P., Cripps, M., Jonker, D., Goel, R., Asmis, T.R., Goodwin, R., Tsvetkova, E., Marginean, H.

Get full text

Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? by Tsvetkova, E V, Asmis, T R

“…Pancreatic cancer is the 4th leading cause of cancer-related death. Complete surgical resection (CR0) is considered the only curative treatment. Most patients…”
Get full text

Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care by Asmis, T.R., Powell, E., Karapetis, C.S., Jonker, D.J., Tu, D., Jeffery, M., Pavlakis, N., Gibbs, P., Zhu, L., Dueck, D.-A., Whittom, R., Langer, C., O'Callaghan, C.J.

“…Background: The interplay between comorbidity, age and performance status (PS) as predictors of outcome in advanced colorectal cancer (ACRC) is poorly…”
Get full text

A retrospective review of cancer treatments and outcomes among Inuit referred from Nunavut, Canada by Asmis, T R, Febbraro, M, Alvarez, G G, Spaans, J N, Ruta, M, Lalany, A, Osborne, G, Goss, G D

“…Cancer is a health concern in Inuit populations. Unique cultural, dietary, and genetic factors and geographic isolation influence cancer epidemiology in this…”
Get full text

Systemic chemotherapy does not increase the risk of gastrointestinal perforation by Asmis, T.R., Capanu, M., Kelsen, D.P., Shah, M.A.

“…Gastrointestinal perforation is a rare complication of gastric cancer. Although there is the perception of chemotherapy aggravating the perforation risk, the…”
Get full text